Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2021 Apr 10:2021.04.09.439166. [Version 1] doi: 10.1101/2021.04.09.439166

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

Hannah A D King, M Gordon Joyce, Ines Elakhal Naouar, Aslaa Ahmed, Camila Macedo Cincotta, Caroline Subra, Kristina K Peachman, Holly H Hack, Rita E Chen, Paul V Thomas, Wei-Hung Chen, Rajeshwer S Sankhala, Agnes Hajduczki, Elizabeth J Martinez, Caroline E Peterson, William C Chang, Misook Choe, Clayton Smith, Jarrett A Headley, Hanne A Elyard, Anthony Cook, Alexander Anderson, Kathryn McGuckin Wuertz, Ming Dong, Isabella Swafford, James B Case, Jeffrey R Currier, Kerri G Lal, Mihret F Amare, Vincent Dussupt, Sebastian Molnar, Sharon P Daye, Xiankun Zeng, Erica K Barkei, Kendra Alfson, Hilary M Staples, Ricardo Carrion, Shelly J Krebs, Dominic Paquin-Proulx, Nicos Karasavvas, Victoria R Polonis, Linda L Jagodzinski, Sandhya Vasan, Paul T Scott, Yaoxing Huang, Manoj S Nair, David D Ho, Natalia de Val, Michael S Diamond, Mark G Lewis, Mangala Rao, Gary R Matyas, Gregory D Gromowski, Sheila A Peel, Nelson L Michael, Kayvon Modjarrad, Diane L Bolton
PMCID: PMC8043445  PMID: 33851155

ABSTRACT

Emergence of novel variants of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) underscores the need for next-generation vaccines able to elicit broad and durable immunity. Here we report the evaluation of a ferritin nanoparticle vaccine displaying the receptor-binding domain of the SARS-CoV-2 spike protein (RFN) adjuvanted with Army Liposomal Formulation QS-21 (ALFQ). RFN vaccination of macaques using a two-dose regimen resulted in robust, predominantly Th1 CD4+ T cell responses and reciprocal peak mean neutralizing antibody titers of 14,000-21,000. Rapid control of viral replication was achieved in the upper and lower airways of animals after high-dose SARS-CoV-2 respiratory challenge, with undetectable replication within four days in 7 of 8 animals receiving 50 µg RFN. Cross-neutralization activity against SARS-CoV-2 variant B.1.351 decreased only ∼2-fold relative to USA-WA1. In addition, neutralizing, effector antibody and cellular responses targeted the heterotypic SARS-CoV-1, highlighting the broad immunogenicity of RFN-ALFQ for SARS-like betacoronavirus vaccine development.

Significance Statement

The emergence of SARS-CoV-2 variants of concern (VOC) that reduce the efficacy of current COVID-19 vaccines is a major threat to pandemic control. We evaluate a SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model that addresses the need for a next-generation, efficacious vaccine with increased pan-SARS breadth of coverage. RFN, adjuvanted with a liposomal-QS21 formulation (ALFQ), elicits humoral and cellular immune responses exceeding those of current vaccines in terms of breadth and potency and protects against high-dose respiratory tract challenge. Neutralization activity against the B.1.351 VOC within two-fold of wild-type virus and against SARS-CoV-1 indicate exceptional breadth. Our results support consideration of RFN for SARS-like betacoronavirus vaccine development.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES